**Winter 2025 Request for Applications**

**PPMI Biofluid Biomarker Program**

#### **Pre-PROPOSAL TEMPLATE**

*Please use the following template to create an executive summary of your experimental plan and upload a PDF copy with your online submission. Text should be no smaller than 11-pt font and not exceed* ***2 pages****. Figures, supporting data, and citation of relevant primary literature supporting the proposal are encouraged and may account for an additional 1 page (which will not count against the 2-page limit). You may delete the instructional text in each box and the box itself below to save space but all narrative headings in the left column must be intact for review.*

*Additionally, please download the ‘Biospecimen Sample Type Worksheet’ from the documents section in the Grant Portal. Upload this document to ‘other attachments’ tab in the application. More information about biosample availability can be found on the* [***PPMI Specimen Website***](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.ppmi-info.org%2Faccess-data-specimens%2Fspecimens%23pd%2F&data=05%7C02%7Catariq%40michaeljfox.org%7Cc413ab576aae437cc11208dd51fab90b%7C7d6a43068a6b4629bcbcb7fe03fc016e%7C0%7C0%7C638756859487732093%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=eoHS%2Fw1pANWH1ZDRrC5pmEUGmn5idaRv%2Biac9NEa8Ys%3D&reserved=0)*under Biosample Inventory. Please contact* *resources@michaeljfox.org* *if you have questions about PPMI inventory.*

Principal Investigator:

Institution/Company:

Project Title:

|  |  |
| --- | --- |
| PROJECT BACKGROUND, IMPACT, & RATIONALE | Do NOT include a background on Parkinson’s disease. Briefly outline the project plan and its significance. Highlight how the proposed work will address the delineated key strategic goals and priorities of PPMI (see Program Overview for details). |
| BIOMARKER ASSAY VALIDATION INFORMATION | PPMI is a study ideally reserved for the verification of progression biomarkers and not for biomarker assay development. As such, include pertinent information demonstrating that the proposed biomarker assay(s) are fully optimized for the requested biospecimens under PPMI’s collection protocol. Provide information on key assay validation parameters on the biospecimens being requested. These include but are not limited to, the dynamic range, precision, sensitivity, specificity, test/retest reliability, and effect of pre-analytical variables. |
| PRELIMINARY DATA | Include preliminary data on the requested biospecimens of human origin, preferably collected under the same conditions as in the PPMI cohort. Specifically, include all pertinent data indicating the utility of the biomarker to monitor PD progression, such as longitudinal assessment, correlation with disease severity/duration measures, or compelling scientific rationale implicating the biomarker to pathogenesis/pathophysiology of PD. |
| SAMPLES REQUESTED | Provide a justification for the number and type of samples requested (including visit number, subject type, any specific clinical parameters, etc.). Include power calculations to justify the sample numbers (ideally from prior data). |
| SUPPLEMENTAL SECTION **FOR PBMC REQUESTS ONLY** | Please review PPMI’s PBMC collection and processing protocol [here](http://www.ppmi-info.org/wp-content/uploads/%20PBMC-Cell-Lines-Biospecimen%20/PPMI-PBMC-Isolation-Overview.docx). Include the following details in your application: 1) Was the preliminary data provided in this application generated using PBMCs collected and processed using the PPMI protocol? If not, 2) did you use fresh or frozen PBMCs? 3) What starting volume of blood do you need for the isolation of PBMCs at the desired cell density for your assay(s)? 4) Please append your PBMC isolation protocol as a supporting document. |
| SUBMISSION OF DATA | All data using PPMI samples must be deposited in the PPMI study database for use by the research community. Describe what data and results will be returned to PPMI and specify timelines for key milestones, project completion, and data return. (Note that biofluid samples are sent blinded and unblinding is performed as part of the data return process).  |